The synthesis of copper nanoparticles (CuNPs) using Wrightia tinctoria (Wt) R.Br extract is defined in this article as being convenient, environmentally friendly, and non-toxic. UV-visible spectrophotometry, FT-IR, XRD, particle size analyser, SEM-EDAX and TEM methods were used to describe the physicochemical properties of Wt extract mediated synthesized CuNPs (Wt-CuNPs). The Wt-CuNPs synthesized was found to be monodispersed and spherical, with an average size of 15 nm. Gas chromatography and mass spectrometry (GC-MS) research revealed that the Wt R.Br plant extract contains various phytochemical compounds. The properties of Wt-CuNPs were verified by the findings of characterization tests. Via in silico molecular docking experiments with established targets, the underlying mechanisms of cytotoxicity against breast cancer and larvicidal behaviour against Aedes aegypti of Wt-CuNPs were investigated. Interestingly, in vitro cytotoxicity studies showed 50% cell death (IC50) of Wt-CuNPs treated MCF-7 cells and Vero Cells (Kidney epithelial cells) were displayed at 119.23 μg.mL−1 and 898.75 μg.mL−1, respectively. Also, Wt-CuNPs showed least LC50 and LC90 values for larvicidal activity against A. aegypti were of 32.10 μg.mL−1 and 21.70 μg.mL−1, respectively. Furthermore, Wt-CuNPs is found to be less toxic and biocompatible in haemolytic assays. The findings clearly showed that biosynthesized Wt-CuNPs have been used as a possible anticancer and larvicidal agent, as well as being environmentally friendly.

Plants and their derived molecules have been traditionally used to manage numerous pathological complications, including male erectile dysfunction (ED). Mimosa pudica Linn. commonly referred to as the touch-me-not plant, and its extract are important sources of new lead molecules in drug discovery research. The main goal of this study was to predict highly effective molecules from M. pudica Linn. for reaching and maintaining penile erection before and during sexual intercourse through in silico molecular docking and dynamics simulation tools. A total of 28 bioactive molecules were identified from this target plant through public repositories, and their chemical structures were drawn using Chemsketch software. Graph theoretical network principles were applied to identify the ideal target (phosphodiesterase type 5) and rebuild the network to visualize the responsible signaling genes, proteins, and enzymes. The 28 identified bioactive molecules were docked against the phosphodiesterase type 5 (PDE5) enzyme and compared with the standard PDE5 inhibitor (sildenafil). Pharmacokinetics (ADME), toxicity, and several physicochemical properties of bioactive molecules were assessed to confirm their drug-likeness property. Molecular dynamics (MD) simulation modeling was performed to investigate the stability of PDE5–ligand complexes. Four bioactive molecules (Bufadienolide (−12.30 kcal mol⁻¹), Stigmasterol (−11.40 kcal mol⁻¹), Isovitexin (−11.20 kcal mol⁻¹), and Apigetrin (−11.20 kcal mol⁻¹)) showed the top binding affinities with the PDE5 enzyme, much more powerful than the standard PDE5 inhibitor (−9.80 kcal mol⁻¹). The four top binding bioactive molecules were further validated for a stable binding affinity with the PDE5 enzyme and conformation during the MD simulation period as compared to the apoprotein and standard PDE5 inhibitor complexes. Further, the four top binding bioactive molecules demonstrated significant drug-likeness characteristics with lower toxicity profiles. According to the findings, the four top binding molecules may be used as potent and safe PDE5 inhibitors and could potentially be used in the treatment of ED.

Cancer immunotherapy is an innovative way of treating cancer by stimulating individual cells to overcome cancer. Widespread biomedical studies were carried out with the aim of exploring immunotherapy cancer therapeutics, and this review spotlights some mechanisms in which it was developed, namely immune checkpoint inhibitors (E.G PD-1/PD-L1, CTLA-4), adoptive cell therapy (e.g., CAR T-cell therapy), and cancer vaccines. Although it has shown clinical benefit in a number of cancer types, including melanoma and non-small-cell lung cancer, several challenges have dampened enthusiasm for this approach, from the differing patient response rates to toxicities. Nanotechnology in drug delivery systems must play a role in overcoming the same. Nanotechnology enables increased specificity and controlled drug release, improved solubility and bioavailability, can treat the tumor specifically, and localized drug delivery at the disease site decreases systemic toxicity. The review also features advances in the construction of lipid-based, polymeric, and inorganic nanoparticles that improve drug stability and allow the delivery of cotherapeutic agents. Nanotechnology-based delivery systems can be used alone or in combination with immunotherapy to assist in improving the immune response, gaining access to the tumor microenvironment, and overcoming biological barriers. Thus, the nano-DDS were both safe and effective in preclinical studies, and ongoing clinical trials have shown that they are capable of increasing the therapeutic index of anticancer drugs. Lastly, the review also discusses current challenges and regulatory issues in advancing these technologies and highlights the importance of further research to devise appropriate methodology for efficient functionalization of nanotechnology for individualized cancer solutions in cancer treatment.

Targeted drug delivery systems are a promising field of research. Nano-engineered material-mediated drug delivery possesses remarkable potential for the treatment of various malignancies. Here, folic acid (FA)-conjugated bovine serum albumin (BSA) nanoparticles (NPs) were used to encapsulate myricetin (Myr). Subsequently, the delivery of Myr via naturally overexpressed folate receptor (FR) to FR-positive breast cancer cells was studied. Myr-loaded BSA NPs were assembled by modified desolvation cross-linking technique. An FA-conjugated carrier, N-hydroxysuccinimide (NHS)-FA ester, was successfully synthesized. Its functional and structural characteristics were confirmed by ultraviolet, Fourier-transform infrared, and proton nuclear magnetic resonance spectroscopy. Biocompatible FA-conjugated, Myr-loaded BSA NPs (FA-Myr-BSA NPs) were successfully formulated using a carbonate/bicarbonate buffer. Their morphology, size, shape, physiological stability, and drug release kinetics were studied. Molecular docking studies revealed that FA-Myr-BSA NPs readily bound non-covalently to folate receptors and facilitated active drug endocytosis. FA-Myr-BSA NPs could trigger fast release of Myr in an acidic medium (pH 5.4), and showed high biocompatibility in a physiological medium. FA-Myr-BSA NPs effectively decreased the viability of MCF-7 cells after 24 h with 72.45 μ g ml ⁻¹ IC ₅₀ value. In addition, FA-Myr-BSA NPs enhanced the uptake of Myr in MCF-7 cells. After incubation, a typical apoptotic morphology of condensed nuclei and distorted membrane bodies was observed. The NPs also targeted mitochondria of MCF-7 cells, significantly increasing reactive oxygen species release and contributing to the loss of mitochondrial membrane integrity. The observed results confirm that the newly developed FA-Myr-BSA NPs can serve as a potential carrier for Myr to increase the anticancer activity of this chemotherapeutic.

Liposome/metal nanoparticle conjugates are found to be a promising carrier tool for effectively delivering wide variety of drugs in a targeted site and without arguing toxic side effects of existing anticancer drugs. In this scenario, the present work was performed to choose Epirubicin-HCl (EPI) as model anticancer drug to formulate citrate stabilized EPI-gold nanoparticles (EPI-GNPs). Further, the biocompatible EPI-GNPs incorporated with lipid bilayer of liposomes formulated to exhibit effective drug delivery system. The biosynthesized EPI-GNPs and its incorporation in a lipid bilayer of liposomes was confirmed by UV-visible spectrophotometer, drug encapsulation, loading capacity, pH stability and drug releasing capacity were studied. Simultaneously, drug and carrier interaction, physical nature, stability, morphological and particle size characteristics were also studied by FTIR, XRD, SEM, TEM and Zeta size analyzer. The obtained characterization data confirmed the properties of EPI-GNPs encapsulated liposomes. The in vitro cytotoxic screening of EPI-GNPs encapsulated liposomes arrest the proliferation of MCF-7 breast cancer cell lines, at 0.1 μ g/ml of liposomes displayed 52% of cell death at 24 h. The EPI-GNPs encapsulated liposomes induced time and dose dependent apoptosis compared with untreated control cancer cells.

Objective: Site-specific and toxic-free drug delivery, is an interesting area of research. Nanoengineered drug delivery systems possess a remarkable potential for effective treatment of various types of cancers. Methods: In this study, novel Folic Acid (FA) conjugated keratin nanoparticles (NPs) were assembled with encapsulation and delivery of Rutin (Rt) into breast cancer cells through the overexpressed folate receptor. The biocompatible, Rt encapsulated FA conjugated keratin NPs (FA@Ker NPs) were successfully formulated by a modified precipitation technique. Their morphological shape and size, size distribution, stability, and physical nature were characterized and confirmed. The drug (Rt) encapsulation efficiency, loading capacity and release kinetics were also studied. Results: The observed results of molecular docking and density functionality theory of active drug (Rt) showed a strong interaction and non-covalent binding of the folate receptor and facilitation of endocytosis in breast cancer cells. Further, in vitro cytotoxic effect of FA@Ker NPs was screened against MCF-7 cancer cells, at 55.2 µg/mL of NPs and found to display 50% of cell death at 24h. Moreover, the NPs enhanced the uptake of Rt in MCF-7 cells, and the apoptotic effect of condensed nuclei and distorted membrane bodies was observed. Also, NPs entered into the mitochondria of MCF-7 cells and significantly increased the level of ROS which led to cell death. Conclusion: The developed FA@Ker NPs might be a promising way to enhance anti-cancer activity without disturbing normal healthy cells.